Coughlin Stoia Attys Seek $18M In Celexa Deal Fees

Law360, New York (February 2, 2009, 12:00 AM EST) -- Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for more than $18 million in fees and expenses.

In a motion filed Friday in the U.S. District Court for the Southern District of New York, lead plaintiffs' counsel Coughlin Stoia Geller Rudman & Robbins LLP asked for 24.5 percent of the proposed $65 million settlement fund and about $1.4 million in expenses plus interest....
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re Forest Laboratories, Inc. Securities Litigation


Case Number

1:05-cv-02827

Court

New York Southern

Nature of Suit

Securities/Commodities

Judge

Richard M. Berman

Date Filed

March 11, 2005

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.